ASTX660 mesylate
Modify Date: 2024-01-11 06:34:07
ASTX660 mesylate structure
|
Common Name | ASTX660 mesylate | ||
|---|---|---|---|---|
| CAS Number | 1799328-90-7 | Molecular Weight | 635.796 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C31H46FN5O6S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of ASTX660 mesylateASTX660 mesylate is a novel potent IAP antagonist that targets the BIR3 domain of cIAP1/2 and XIAP with IC50 of 12 nM and <40 nM; potently inhibits association between XIAP and caspase 9 in HEK293 cell line with EC50 of 2.8 nM, binds to and leads to the degradation of cIAP1/2 and stabilisation of NIK in cell; induces apoptosis in MDA-MB-231 cells with EC50 of 1.8 nM, which is TNF-α-dependent; inhibits tumor growth in mice bearing breast and melanoma tumor xenografts. Blood Cancer Phase 2 Clinical |
| Name | ASTX660 mesylate |
|---|
| Description | ASTX660 mesylate is a novel potent IAP antagonist that targets the BIR3 domain of cIAP1/2 and XIAP with IC50 of 12 nM and <40 nM; potently inhibits association between XIAP and caspase 9 in HEK293 cell line with EC50 of 2.8 nM, binds to and leads to the degradation of cIAP1/2 and stabilisation of NIK in cell; induces apoptosis in MDA-MB-231 cells with EC50 of 1.8 nM, which is TNF-α-dependent; inhibits tumor growth in mice bearing breast and melanoma tumor xenografts. Blood Cancer Phase 2 Clinical |
|---|---|
| References | References 1. Ward GA, et al. Mol Cancer Ther. 2018 Apr 25. pii: molcanther.0848.2017. View Related Products by Target IAP Blood Cancer |
| Molecular Formula | C31H46FN5O6S |
|---|---|
| Molecular Weight | 635.796 |